作为世界博彩公司十大排名癌症患者，您将有独特的机会参与大约100项临床研究试验中的一项或多项，这些试验涉及许多癌症类型的新疗法.

作为世界博彩公司十大排名的病人你可能有独特的机会参加心房纤颤的临床研究试验, congestive heart failure, lipid disorders, 心脏病发作和更多的心脏病状态.

作为世界博彩公司十大排名的病人你可能有机会参加腹腔疾病的临床研究试验, Crohn’s disease, ulcerative colitis, reflux disease, 肝炎和许多其他肠胃疾病.

临床试验研究预防、检测和治疗疾病的新方法. 如果你参与研究，你将帮助推进新的研究性医学疗法. 

Title: CAMBRIA-1: A Phase III, Open-Label, 评估Camizestrant (AZD9833)延长治疗的有效性和安全性的随机研究, a Next Generation, 口服选择性雌激素受体降降剂(口服选择性雌激素受体降降剂)与标准内分泌治疗(芳香酶抑制剂或他莫昔芬)在ER+/HER2-早期乳腺癌和中度或高度复发的患者中进行比较，这些患者已经完成了明确的局部治疗和至少2年的标准辅助内分泌治疗，没有疾病复发
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
Details (Indentifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, 评估Camizestrant (AZD9833)有效性和安全性的随机研究, a Next-Generation, 口服选择性雌激素受体降降剂(口服选择性雌激素受体降降剂)与标准内分泌治疗(芳香化酶抑制剂或他莫昔芬)作为ER+/HER2-早期乳腺癌和中高或高风险复发患者的辅助治疗，完成了明确的局部区域治疗，没有疾病证据
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sponsors: Astra Zeneca
Details (Indentifier #): NCT04964934
Title: EA5181:随机III期试验MEDI4736 (Durvalumab)作为并发和巩固治疗或单独巩固治疗不可切除的3期NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT04092283
Title: EA6141, Nivolumab + Ipilimumab + Sargramostim与Nivolumab + Ipilimumab在不可切除的III期或IV期黑色素瘤患者中的随机II/III期研究
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT02339571
Title: EA6194, 新辅助派姆单抗单独或联合CMP-001治疗可手术黑色素瘤患者的II期随机研究:疗效和生物标志物研究
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT04708418
Title: 简易吸氧器在氧依赖患者中的临床应用评价
Department: Pulmonary
Diagnosis: Lung - COPD
Principal Investigator: 詹姆斯J沃尔什，医学博士，MSHA, FACP, FCCP
Sponsors: Effortless
Details (Indentifier #): NA
Title: Vallania研究:发展多组学血液检测用于癌症筛查的病例对照研究
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Freenome
Details (Indentifier #): NCT05254834
Title: 中期FDG-PET/CT预测HER2阳性乳腺癌对新辅助治疗的反应:直接试验
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT05710328
Title: LIBREXIA-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, 米尔维克斯的有效性和安全性评价的主动对照研究, 口服因子XIa抑制剂, 心房颤动患者与阿哌沙班的对比研究
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Edo Kaluski, MD, FACC, FESC, FSCAI
Sponsors: Janssen
Details (Indentifier #): NCT05757869
Title: 口服西沙必利治疗难治性胃食管反流病和其他胃肠运动障碍的有限准入方案. CIS-USA-154
Department: Gastroenterology
Diagnosis: 肠胃-其他
Principal Investigator: Thomas J McDonald, MD
Sub-Investigator(s):
Sponsors: Janssen
Details (Indentifier #): none
Showing 11-20 of 41 Results